Skip to main content
Erschienen in: Tumor Biology 1/2014

01.01.2014 | Research Article

Association between RAD51 gene polymorphism (-135G/C) and susceptibility of myelodysplastic syndrome and acute leukemia: evidence based on a meta-analysis

verfasst von: Ya-zhou He, Xin Hu, Xiao-sa Chi, Yuan-chuan Zhang, Xiang-Bing Deng, Ming-tian Wei, Zi-qiang Wang, Yan-hong Zhou

Erschienen in: Tumor Biology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Study results on the association between RAD51 gene -135G/C polymorphism and risk of myelodysplastic syndrome (MDS) or acute leukemia are inconsistent. A meta-analysis was conducted to identify the association. A systematic search was performed in PubMed, Embase, CNKI, VIP, Wanfang databases to collect all relevant studies until January 2013. Meta-analysis was carried out using fixed/random model by Review Manager 5.1 and STATA10.0. A total of 10 eligible studies with 2,656 patients and 3,725 controls were included in meta-analysis. Significant association was detected between -135G/C polymorphism and increased MDS risk (CC + GC vs. GG: OR = 1.46, 95 % CI = 1.11–1.92; CC vs. GC + GG: OR = 2.45, 95 % CI = 1.23–4.89), while no association was observed for acute leukemia. Subgroup analysis by subtypes of acute leukemia and ethnicity showed no significant results either. Our meta-analysis indicated that the -135G/C polymorphism might be associated with increased susceptibility of MDS. However, lack of evidence supported association of this polymorphism with acute leukemia. Additional well-designed studies with larger samples are required to verify our results.
Literatur
1.
2.
Zurück zum Zitat Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.PubMedCrossRef Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.PubMedCrossRef
3.
Zurück zum Zitat Wang LL, Gao C, Chen BA. Research progress on mechanism of MDS transformation into AML. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011;19:254–9.PubMed Wang LL, Gao C, Chen BA. Research progress on mechanism of MDS transformation into AML. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011;19:254–9.PubMed
4.
Zurück zum Zitat Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008;22:240–8.PubMedCrossRef Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008;22:240–8.PubMedCrossRef
5.
Zurück zum Zitat Bjork J, Johansson B, Broberg K, Albin M. Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case–control study. Leuk Res. 2009;33:788–91.PubMedCrossRef Bjork J, Johansson B, Broberg K, Albin M. Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case–control study. Leuk Res. 2009;33:788–91.PubMedCrossRef
6.
Zurück zum Zitat Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist. 2010;15:1083–101.PubMedCrossRef Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist. 2010;15:1083–101.PubMedCrossRef
7.
Zurück zum Zitat Kitamura T, Watanabe-Okochi N, Inoue D, Togami K, Uchida T, Kagiyama Y, et al. Molecular mechanisms underlying leukemic transformation of myelodysplastic syndromes (MDS) and chronic myelogenous leukemia (CML). Jpn J Clin Hematol. 2012;53:734–9. Kitamura T, Watanabe-Okochi N, Inoue D, Togami K, Uchida T, Kagiyama Y, et al. Molecular mechanisms underlying leukemic transformation of myelodysplastic syndromes (MDS) and chronic myelogenous leukemia (CML). Jpn J Clin Hematol. 2012;53:734–9.
8.
Zurück zum Zitat Finch SC. Radiation-induced leukemia: lessons from history. Best Pract Res Clin Hematol. 2007;20:109–18.CrossRef Finch SC. Radiation-induced leukemia: lessons from history. Best Pract Res Clin Hematol. 2007;20:109–18.CrossRef
9.
Zurück zum Zitat Alexander FE, Patheal SL, Biondi A, Brandalise S, Cabrera ME, Chan LC, et al. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res. 2001;61:2542–6.PubMed Alexander FE, Patheal SL, Biondi A, Brandalise S, Cabrera ME, Chan LC, et al. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res. 2001;61:2542–6.PubMed
10.
Zurück zum Zitat Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411:366–74.PubMedCrossRef Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411:366–74.PubMedCrossRef
11.
Zurück zum Zitat Agarwal S, Tafel AA, Kanaar R. DNA double-strand break repair and chromosome translocations. DNA Repair. 2006;5:1075–81.PubMedCrossRef Agarwal S, Tafel AA, Kanaar R. DNA double-strand break repair and chromosome translocations. DNA Repair. 2006;5:1075–81.PubMedCrossRef
12.
Zurück zum Zitat Baumann P, West SC. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci. 1998;23:247–51.PubMedCrossRef Baumann P, West SC. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci. 1998;23:247–51.PubMedCrossRef
13.
Zurück zum Zitat Thacker J. The RAD51 gene family, genetic instability, and cancer. Cancer Lett. 2005;219:125–35.PubMedCrossRef Thacker J. The RAD51 gene family, genetic instability, and cancer. Cancer Lett. 2005;219:125–35.PubMedCrossRef
14.
15.
16.
Zurück zum Zitat Kawabata M, Kawabata T, Nishibori M. Role of recA/RAD51 family proteins in mammals. Acta Med Okayama. 2005;59:1–9.PubMed Kawabata M, Kawabata T, Nishibori M. Role of recA/RAD51 family proteins in mammals. Acta Med Okayama. 2005;59:1–9.PubMed
17.
Zurück zum Zitat Rollinson S, Smith AG, Allan JM, Adamson PJ, Scott K, Skibola CF, et al. RAD51 homologous recombination repair gene haplotypes and risk of acute myeloid leukemia. Leukemia Res. 2007;31:169–74.CrossRef Rollinson S, Smith AG, Allan JM, Adamson PJ, Scott K, Skibola CF, et al. RAD51 homologous recombination repair gene haplotypes and risk of acute myeloid leukemia. Leukemia Res. 2007;31:169–74.CrossRef
18.
Zurück zum Zitat Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res. 2004;10:2675–80.PubMedCrossRef Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res. 2004;10:2675–80.PubMedCrossRef
19.
Zurück zum Zitat Fabiani E, D’Alo F, Scardocci A, Greco M, Di Ruscio A, Criscuolo M, et al. Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes. Leuk Res. 2009;33:1068–71.PubMedCrossRef Fabiani E, D’Alo F, Scardocci A, Greco M, Di Ruscio A, Criscuolo M, et al. Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes. Leuk Res. 2009;33:1068–71.PubMedCrossRef
20.
Zurück zum Zitat Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327:557–60.PubMedCrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327:557–60.PubMedCrossRef
21.
Zurück zum Zitat Li L, Yang L, Zhang Y, Xu Z, Qin T, Hao Y, et al. Detoxification and DNA repair genes polymorphisms and susceptibility of primary myelodysplastic syndromes in Chinese population. Leuk Res. 2011;35:762–5.PubMedCrossRef Li L, Yang L, Zhang Y, Xu Z, Qin T, Hao Y, et al. Detoxification and DNA repair genes polymorphisms and susceptibility of primary myelodysplastic syndromes in Chinese population. Leuk Res. 2011;35:762–5.PubMedCrossRef
22.
Zurück zum Zitat Baumann Kreuziger LM, Steensma DP. RAD51 and XRCC3 polymorphism frequency and risk of myelodysplastic syndromes. Am J Hematol. 2008;83:822–3.PubMedCrossRef Baumann Kreuziger LM, Steensma DP. RAD51 and XRCC3 polymorphism frequency and risk of myelodysplastic syndromes. Am J Hematol. 2008;83:822–3.PubMedCrossRef
23.
Zurück zum Zitat Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, et al. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children’s Oncology Group. Leukemia. 2008;22:265–72.PubMedCentralPubMedCrossRef Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, et al. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children’s Oncology Group. Leukemia. 2008;22:265–72.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Hamdy MS, El-Haddad AM, Bahaa El-Din NM, Makhlouf MM, Abdel-Hamid SM. RAD51 and XRCC3 gene polymorphisms and the risk of developing acute myeloid leukemia. J Investig Med: the official publication of the American Federation for Clinical Research. 2011;59:1124–30. Hamdy MS, El-Haddad AM, Bahaa El-Din NM, Makhlouf MM, Abdel-Hamid SM. RAD51 and XRCC3 gene polymorphisms and the risk of developing acute myeloid leukemia. J Investig Med: the official publication of the American Federation for Clinical Research. 2011;59:1124–30.
25.
Zurück zum Zitat Voso MT, Fabiani E, D’Alo F, Guidi F, Di Ruscio A, Sica S, et al. Increased risk of acute myeloid leukemia due to polymorphisms in detoxification and DNA repair enzymes. Ann Oncol. 2007;18:1523–8.PubMedCrossRef Voso MT, Fabiani E, D’Alo F, Guidi F, Di Ruscio A, Sica S, et al. Increased risk of acute myeloid leukemia due to polymorphisms in detoxification and DNA repair enzymes. Ann Oncol. 2007;18:1523–8.PubMedCrossRef
26.
Zurück zum Zitat Yang L, Liu L, Mi YC, Li JY, Ma XT, Ai XF, et al. Relationship between RAD51-G135C/XRCC3-C241T polymorphisms and development of acute myeloid leukemia with recurrent chromosome translocation. Zhonghua Xueyexue Zazhi. 2011;32:299–303.PubMed Yang L, Liu L, Mi YC, Li JY, Ma XT, Ai XF, et al. Relationship between RAD51-G135C/XRCC3-C241T polymorphisms and development of acute myeloid leukemia with recurrent chromosome translocation. Zhonghua Xueyexue Zazhi. 2011;32:299–303.PubMed
27.
Zurück zum Zitat Zhang ZQ, Yang L, Zhang Y, Yang YH, Nie L, Li L, et al. Relationship between NQO1C(609T), RAD51(G135C), XRCC3(C241T) single nucleotide polymorphisms and acute lymphoblastic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17:523–8.PubMed Zhang ZQ, Yang L, Zhang Y, Yang YH, Nie L, Li L, et al. Relationship between NQO1C(609T), RAD51(G135C), XRCC3(C241T) single nucleotide polymorphisms and acute lymphoblastic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17:523–8.PubMed
Metadaten
Titel
Association between RAD51 gene polymorphism (-135G/C) and susceptibility of myelodysplastic syndrome and acute leukemia: evidence based on a meta-analysis
verfasst von
Ya-zhou He
Xin Hu
Xiao-sa Chi
Yuan-chuan Zhang
Xiang-Bing Deng
Ming-tian Wei
Zi-qiang Wang
Yan-hong Zhou
Publikationsdatum
01.01.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1085-4

Weitere Artikel der Ausgabe 1/2014

Tumor Biology 1/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.